Company Focus
Bristol Myers Squibb
Latest Bristol Myers Squibb News
Biotechnology
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Related News
Insights
Company Spotlight
A clinical-stage biotech company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders.
Latest News & Features of interest to Bristol Myers Squibb
Biotechnology
US pharma giant Merck & Co is to buy CN201, an investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases, from privately-held Chinese biotech Curon Biopharmaceutical. 9 August 2024
Biotechnology
Citius Pharmaceuticals has won US Food and Drug Administration (FDA) approval for Lymphir (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of relapsed or refractory (r/r) cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. 9 August 2024
Biotechnology
Australian biotech Neuren Pharmaceuticals today announced top-line results from its Phase II clinical trial of NNZ-2591. 9 August 2024
Pharmaceutical
In a significant move aimed at expediting access to life-saving medications for Indian patients, the Indian government has waived the requirement for conducting local clinical trials for drugs that have already received approval from regulatory authorities in the USA, UK, Japan, Australia, Canada, or the European Union. 9 August 2024
Biotechnology
US biotech Gilead Sciences announced second quarter 2024 financials after markets closed on Thursday. 9 August 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Crexont (carbidopa and levodopa; formerly IPX2023) extended-release capsules for the treatment of Parkinson’s disease (PD), from US drugmaker Amneal Pharmaceuticals. 9 August 2024
Pharmaceutical
US drugmaker Eli Lilly wowed investors with expectation-busting second-quarter financial results on Thursday, sending its shares spiralling 8% higher by early afternoon trading. 8 August 2024
Biotechnology
US AI-enabled biotech Recursion and UK-based Exscientia today announced the companies have entered into a definitive merger agreement. 8 August 2024
Biotechnology
Germany-based Medigene’s shares were down 3.7% at 1.04 euros in late afternoon trading, after it revealed a collaboration with China’s WuXi Biologics. 8 August 2024
Biotechnology
Vertex Pharmaceuticalsrevealed a reimbursement agreement with NHS England for eligible transfusion-dependent beta thalassemia (TDT) patients to access the CRISPR/Cas9 gene-edited therapy, Casgevy (exagamglogene autotemcel), from today. 8 August 2024
Latest In Brief for Bristol Myers Squibb
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Latest Relevant Ones To Watch News
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
8 October 2024
24 September 2024
24 September 2024
19 September 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze